🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. Zibotentan, DAPAGLIFLOZIN, Zibotentan placebo, Dapagliflozin placebo

    AstraZeneca AB

    Cirrhosis of the liver is a condition in which the liver is scarred and damaged

    phase 2 small molecule active

    1 trial

  2. aleniglipron or placebo

    Structure Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  3. alpha 1H, Placebo product for Alpha1H

    Lacuna Pharma Pty Ltd

    Non-muscle invasive bladder cancer awaiting transurethral surgery

    phase 2 small molecule active

    1 trial

  4. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, semaglutide, cagrilintide, cagrilintide, cagrilintide semaglutide, cagrilintide semaglutide, semaglutide, semaglutide, semaglutide, FINERENONE , DAPAGLIFLOZIN , semaglutide, cagrilintide, ENALAPRIL , cagrilintide, cagrilintide, cagrilintide semaglutide

    NovoThirteen

    Chronic Kidney Disease, Type 2 diabetes

    phase 2 small molecule active

    1 trial

  5. cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, Placebo (zalfermin) + Placebo (semaglutide), semaglutide, Placebo (cagrilintide) + placebo (semaglutide), cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, zalfermin, cagrilintide, cagrilintide

    NovoThirteen

    alcohol-related liver disease

    phase 2 small molecule active

    1 trial

  6. efinopegdutide, efinopegdutide, efinopegdutide, Placebo to MK-6024, efinopegdutide

    Merck Sharp and Dohme

    Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  7. elafibranor, Placebo of Elafibranor, elafibranor

    Ipsen

    Primary Sclerosing Cholangitis

    phase 2 small molecule active

    1 trial

  8. experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo

    Universal Integrated

    Anovulatory Infertility

    phase 2 small molecule active

    1 trial

  9. masitinib, masitinib, Placebo to 100mg masitinib, Placebo to 200mg masitinib

    AB Science

    Mast cell activation syndrome

    phase 2 small molecule active

    1 trial

  10. placebo

    Nektar Therapeutics UK Limited

    Opioid Induced Constipation (OIC)

    phase 2 small molecule completed

    1 trial

  11. placebo

    Universal Integrated

    Postprandial Distress Syndrome

    phase 2 small molecule active

    1 trial

  12. placebo

    The First People's Hospital of Lianyungang

    COVID-19 Thalidomide

    phase 2 small molecule active

    1 trial

  13. placebo PH20 SC PFS, Vyvgart 1 000 mg solution for injection in pre-filled syringe

    argenx

    Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  14. placebo mouthwash

    BRIGHT MINDS BIOSCIENCES INC.

    Dentinal Hypersensitivity

    phase 2 other completed

    1 trial

  15. placebo of BAY 3427080, BAY 3427080

    Bayer AG

    Sleep disturbances associated with menopause

    phase 2 small molecule active

    1 trial

  16. rhNGF New Lyo Formulation, OXYBUPROCAINE , SODIUM CHLORIDE , rhNGF New Lyo Formulation, The placebo consists of a lyophilized product packaged in 2R siliconized glass class I vials closed with a stopper and a flip off cap and administered after reconstitution with 2mL of diluent contained into a 2R glass class I vials closed with a stopper and a flip off cap. The diluent consists of DMSO, Sesame Extract 98%, Kollifor HS 0.15%, Sodium Chloride, Water For Injection. The product is reconstituted using an ada

    Dompe' Farmaceutici S.p.A.

    Dry Eye

    phase 2 small molecule active

    1 trial

  17. tamuzimod, tamuzimod, tamuzimod, VTX002 placebo film-coated tablets matching VTX002, tamuzimod

    Lacuna Pharma Pty Ltd

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  18. telaprevir or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  19. tovinontrine-matching placebo, immediate-release tablet, Tovinontrine

    Lacuna Pharma Pty Ltd

    chronic heart failure

    phase 2 small molecule active

    1 trial

  20. tulisokibart, Placebo to MK-7240

    Merck Sharp and Dohme

    Psoriatic arthritis​​

    phase 2 small molecule active

    1 trial

  21. tulisokibart, Placebo to MK-7240 (tulisokibart)

    Merck Sharp and Dohme

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  22. 15O-WATER, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, AZD3427, Dopamin Fresenius 50 mg/5 ml, Konzentrat zur Herstellung einer Infusionslösung, Placebo for AZD3427 or AZD3427 diluent

    AstraZeneca AB

    Heart failure with reduced ejection fraction, Renal impairment

    phase 1 small molecule active

    1 trial

  23. A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTIPLE RISING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF DEURUXOLITINIB IN HEALTHY ADULTS

    Lacuna Pharma Pty Ltd

    alopecia areata

    phase 1 other active

    1 trial

  24. A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus

    AstraZeneca AB

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources